102 related articles for article (PubMed ID: 7506034)
21. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.
Martin-Fontecha A; Cavallo F; Bellone M; Heltai S; Iezzi G; Tornaghi P; Nabavi N; Forni G; Dellabona P; Casorati G
Eur J Immunol; 1996 Aug; 26(8):1851-9. PubMed ID: 8765031
[TBL] [Abstract][Full Text] [Related]
22. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation.
Chaux P; Moutet M; Faivre J; Martin F; Martin M
Lab Invest; 1996 May; 74(5):975-83. PubMed ID: 8642792
[TBL] [Abstract][Full Text] [Related]
23. B7-1 expression by a non-antigen presenting cell-derived tumor.
Antonia SJ; Muñoz-Antonia T; Soldevila G; Miller J; Flavell RA
Cancer Res; 1995 Jun; 55(11):2253-6. PubMed ID: 7538898
[TBL] [Abstract][Full Text] [Related]
24. Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40.
Ruybal P; Gravisaco MJ; Barcala V; Escalada A; Di Sciullo P; Waldner C; Mongini C
Vaccine; 2008 Jan; 26(5):697-705. PubMed ID: 18155328
[TBL] [Abstract][Full Text] [Related]
25. Overcoming T cell ignorance by providing costimulation. Implications for the immune response against cancer.
Chen L
Adv Exp Med Biol; 1998; 451():159-65. PubMed ID: 10026867
[No Abstract] [Full Text] [Related]
26. Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens.
Melero I; Bach N; Chen L
Life Sci; 1997; 60(23):2035-41. PubMed ID: 9180357
[TBL] [Abstract][Full Text] [Related]
27. On the role of costimulation in tumor immunity.
Hellström KE; Hellström I; Linsley P; Chen L
Ann N Y Acad Sci; 1993 Aug; 690():225-30. PubMed ID: 7690212
[No Abstract] [Full Text] [Related]
28. Tumor immunology, T cell maturation, and T cell neoplasia.
Weissman IL
Prog Exp Tumor Res; 1980; 25():193-218. PubMed ID: 6986632
[No Abstract] [Full Text] [Related]
29. Animal experiments on the role of T lymphocytes in the course of antineoplastic chemotherapy. I. Chemotherapy and tumor-specific immunity.
Bier H; Bier J
ORL J Otorhinolaryngol Relat Spec; 1987; 49(1):48-55. PubMed ID: 3494221
[TBL] [Abstract][Full Text] [Related]
30. Antigenic properties of other experimental tumors.
KLEIN G; KLEIN E
Cold Spring Harb Symp Quant Biol; 1962; 27():463-70. PubMed ID: 14033355
[No Abstract] [Full Text] [Related]
31. Tumor immunity requires border patrol to fight the enemy within.
Amsen D; Hombrink P; van Lier RAW
Nat Immunol; 2017 Jul; 18(8):870-872. PubMed ID: 28722713
[No Abstract] [Full Text] [Related]
32. Clinicopathologic Evaluation of CD80, CD86, and PD-L1 Expressions with Immunohistochemical Methods in Malignant Melanoma Patients.
Cobankent Aytekin E; Unal B; Bassorgun CI; Ozkan O
Turk Patoloji Derg; 2024; 40(1):16-26. PubMed ID: 37614091
[TBL] [Abstract][Full Text] [Related]
33. CAR-T cells: Early successes in blood cancer and challenges in solid tumors.
Dana H; Chalbatani GM; Jalali SA; Mirzaei HR; Grupp SA; Suarez ER; Rapôso C; Webster TJ
Acta Pharm Sin B; 2021 May; 11(5):1129-1147. PubMed ID: 34094824
[TBL] [Abstract][Full Text] [Related]
34. Engineering anti-cancer nanovaccine based on antigen cross-presentation.
Warrier VU; Makandar AI; Garg M; Sethi G; Kant R; Pal JK; Yuba E; Gupta RK
Biosci Rep; 2019 Oct; 39(10):. PubMed ID: 31652460
[TBL] [Abstract][Full Text] [Related]
35. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.
Mirzaei HR; Rodriguez A; Shepphird J; Brown CE; Badie B
Front Immunol; 2017; 8():1850. PubMed ID: 29312333
[TBL] [Abstract][Full Text] [Related]
36. Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade.
Bai J; Gao Z; Li X; Dong L; Han W; Nie J
Oncotarget; 2017 Dec; 8(66):110693-110707. PubMed ID: 29299180
[TBL] [Abstract][Full Text] [Related]
37. Immune checkpoint inhibitors in cancer therapy.
Webb ES; Liu P; Baleeiro R; Lemoine NR; Yuan M; Wang YH
J Biomed Res; 2018 Sep; 32(5):317-326. PubMed ID: 28866656
[TBL] [Abstract][Full Text] [Related]
38. PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.
Wang J; Yuan R; Song W; Sun J; Liu D; Li Z
J Hematol Oncol; 2017 Jan; 10(1):34. PubMed ID: 28122590
[TBL] [Abstract][Full Text] [Related]
39. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
Boussiotis VA
N Engl J Med; 2016 Nov; 375(18):1767-1778. PubMed ID: 27806234
[No Abstract] [Full Text] [Related]
40.
Sasaki H; Tatemaysu T; Okuda K; Moriyama S; Yano M; Fujii Y
Mol Clin Oncol; 2014 Nov; 2(6):1035-1042. PubMed ID: 25279194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
